Non-Small-Cell Lung Cancer: Perspectives on Key Data

EP. 1: FLAURA Trial: Impact of OS Data in Advanced NSCLC

October 18th 2019

EP. 2: Strategies for Approaching Frontline Therapy in EGFR+ NSCLC

October 18th 2019

EP. 3: LIBRETTO-001: RET-Fusion Positive Metastatic NSCLC

October 18th 2019

EP. 4: Targeted Therapy for KRAS-Mutant NSCLC

October 18th 2019

EP. 5: CheckMate 227: Combining CTLA-4 and PD-L1 in NSCLC

October 18th 2019

EP. 6: CheckMate 817 Dual Immune-Checkpoint Inhibition in ECOG PS 2

October 18th 2019

EP. 7: Role of I/O With Chemotherapy in Advanced Squamous NSCLC

October 18th 2019

EP. 8: Long-Term Outcomes With PD-1 Monotherapy in NSCLC

October 18th 2019

EP. 9: I/O + Chemotherapy in Treatment-Naive ES-SCLC

October 18th 2019

EP. 10: CASPIAN Trial: Durvalumab and Chemotherapy in ES-SCLC

October 18th 2019

EP. 11: Role of Tumor Mutational Burden in NSCLC

October 18th 2019

EP. 12: Tumor Mutational Burden in Key Phase III Trials of NSCLC

October 18th 2019

EP. 13: Final Thoughts on Targeted Therapy and I/O Agents in NSCLC

October 18th 2019